In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
|Articles|August 8, 2011
Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research
Advertisement
Eurofins Optimed Clinical Research
and
Spaulding Clinical Research
announced a joint partnership agreement. This partnership leverages the strengths of both companies and facilitates collaboration on integrated clinical services to engage pharmaceutical clients who demand a global footprint.
"The culture of excellence and research facilities designed to execute high-quality studies was very impressive to our team. We felt immediately comfortable with the Optimed clinical team and witnessed their efficient execution of studies," states Daniel Selness, General Manager and Senior Vice President of Operations. "We were very impressed that Spaulding achieved ISO certification, which is not common among US clinical research facilities. Their systems approach with Electronic Data Capture is something that we have been looking to implement, so the partnership will allow us to consider how to collaborate more closely as these systems are put in place," states Yves Donazzolo, MD, CEO and President of Optimed.
Eurofins Optimed and Spaulding Clinical offer a full range of global services to the Pharmaceutical industry and Biotechnology companies from study design through study execution/conduct, data management, statistical analysis, and medical writing. Both companies excel in TQT, first-in-human, multiple rising dose, bioavailability/bioequivalence, drug interaction, food effect studies and Proof-Of-Concept studies in patients.
Advertisement
Related to this article
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.
Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
4
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
5